Accesswire
17 Jun 2026, 20:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
IBAT's DLE technology achieved 98% lithium recovery and 99+% contaminant rejection over 1,200 cycles using real-world brine samples from multiple global regions. — Proven technical efficacy across diverse brine compositions is the primary catalyst for moving from R&D to commercial viability.
+0.80The company is currently in negotiations with several counterparties for the commercial deployment of its existing modular DLE plant. — Transitioning from testing to commercial agreements provides a direct path to scalable revenue and market validation.
+0.60Full-year revenue declined to $164 thousand from $871 thousand in the prior year. — The significant drop in revenue highlights the company's current lack of commercial scale and reliance on small-scale testing fees.
-0.40Continue reading
6 related stories
Search tags
IBAT ended the fiscal year with a cash position of $9.2 million and recently raised $2.0 million in new equity financing. — While providing a short-term liquidity runway, the need for equity financing underscores the burn rate of the pre-revenue operation.
+0.20Which stocks this story touches
The company reported strong technical results with 98% lithium recovery and transitioned to a net income position for the full year.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
12m ago
